MedTrace Logo

Lidocaine-based Versus Opioid-based Induction of Anesthesia in Emergency Laparotomy

NCT06772727 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 149

Last updated 2026-03-05

No results posted yet for this study

Summary

Lidocaine-based anesthesia had been recently reported as a successful regimen for induction of anesthesia in elderly population with better hemodynamic profile than opioid-based induction. The investigators hypothesize that lidocaine-based induction of anesthesia would provide superior hemodynamic profile compared to conventional opioid-based induction of anesthesia in emergency laparotomy.

Conditions

  • Post-induction Hypotension
  • Lidocaine
  • Opioid
  • Emergency Laparotomy

Interventions

DRUG

Lidocaine

After preoxygenation with 100% oxygen for 3 minutes, the study drug (lidocaine) will be administered. Patients will receive 1 mg/kg lidocaine of 10 mg/mL lidocaine solution (prepared by diluting 5 mL of lidocaine 20% in saline to a total volume of 10 mL)

DRUG

Fentanyl

After preoxygenation with 100% oxygen for 3 minutes, the study drug (fentanyl) will be administered. Patients will receive 1 mcg/kg fentanyl of 10 mcg/mL fentanyl solution (prepared by diluting 100 mcg fentanyl in saline to a total volume of 10 mL).

DRUG

Propofol

After administration of the study drug, all patients will receive 2 mg/kg propofol intravenously

DRUG

Succinyl choline

After loss of consciousness, 1 mg/kg succinyl choline will be administered over 5 seconds, and tracheal intubation will be done through direct laryngoscopy after 60 seconds.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Jehan Elkholy, M.D. · Cairo University

  • Eman F Ali,, M.D. · Cairo University

  • Kareem MA Nawwar, M.D. · Cairo University

  • Mohsen M Waheeb, M.D. · Cairo University

  • Samar M Abdel Azeim Ghazala, M.Sc. · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2025-10-30
Completion
2025-10-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06772727 on ClinicalTrials.gov